Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 24, 2014
Pharmacy Choice - News - Pharmaceutical Development - April 24, 2014

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 243     Next >>     Go To Page:

4/24/14 - Actinium to Present at RedChip Global Online CEO Conference April 24
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 12:30 PM ET at RedChip s Global Online CEO Conference. Actinium Pharmaceuticals, Inc. is a New York- based biopharmaceutical company developing innovative targeted...
4/24/14 - Alkermes Reports Positive Phase 3 Study Results [Professional Services Close - Up]
Alkermes announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. "These statistically significant efficacy data demonstrate aripiprazole lauroxil's ability to provide clinically meaningful symptom control in patients struggling with...
4/24/14 - Axiom Food's Oryzatein Becomes First Rice Protein Ever To Earn GRAS Approval
By a News Reporter-Staff News Editor at Politics& Government Week On the heels of a 2013 double-blind clinical trial which proved Axiom Food's Oryzatein plant-based brown rice protein equals animal-based whey in building and repairing muscles, Oryzatein has now become the very first brown rice protein to be granted GRAS approval. The GRAS appr
4/24/14 - Bavarian Nordic Welcomes Gerard van Odijk as New Chairman of the Board
KVISTGAARD, Denmark, April 24, 2014- Bavarian Nordic A/S announced today, that following the ordinary general meeting, the board has elected Gerard van Odijk, M.D. as new chairman of the board of Bavarian Nordic. van Odijk has served as board member in Bavarian Nordic since 2008. He is an independent advisor for the pharmaceutical industry in which
4/24/14 - BRIEF: Coral Gables drug company to make new medicine available at no cost [The Miami Herald :: ]
April 23 Coral Gables- based Catalyst Pharmaceutical Partners soon will make its investigational drug Firdapse available at no cost to patients with a certain autoimmune disorder. Catalyst said it expects to submit an application for Firdapse's approval with the U.S. Food and Drug Administration next year. Catalyst has been leading the developmen
4/24/14 - Can new drug extend lives of Southwest Florida men with prostate cancer? [Naples Daily News, Fla. :: ]
April 24 NAPLES Walter Corbin strikes up an easy conversation with the medical technicians who prepare him for an intravenous injection of Xofigo, a recently approved drug for advanced prostate cancer. His commute to the oncology center includes a boat ride from his winter home on exclusive Useppa Island, north of Pine Island Sound in Lee Count
4/24/14 - Celgene Acquires Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Celgene Corporation entered into a global license agreement with Nogra Pharma Limited, a private pharmaceutical company based in Dublin, Ireland, to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn s disease and other indications. Based upon these results
4/24/14 - Celgene Announces Agreement with Nogra Pharma Limited to Develop, Commercialize GED-0301
Celgene Corporation entered into a global license agreement with Nogra Pharma Limited, a private pharmaceutical company based in Dublin, Ireland, to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease and other indications. Based upon these results,..
4/24/14 - Cubist Submits New Drug Application for Investigational Antibiotic Ceftolozane/tazobactam [Health & Beauty Close - Up]
Cubist Pharmaceuticals, Inc. announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of its investigational antibiotic ceftolozane/ tazobactam for the treatment of Complicated Urinary Tract Infections and Complicated Intra-Abdominal Infections. The NDA submission is based on positive data from...
4/24/14 - Data from Upsher-Smith's Epilepsy Portfolio to be Presented at Meeting of the American Academy Of Neurology [Health & Beauty Close - Up]
Upsher-Smith Laboratories, Inc.. a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, will highlight new pooled phase 1 data from studies in healthy adults comparing the adverse event profile of USL255 with immediate-release topiramate in a poster presentation at the 66
4/24/14 - Emergent BioSolutions Reports Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease [Health & Beauty Close - Up]
Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BioThrax for post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis. "Emergent is pleased with FDA's Orphan Drug Designation of BioThrax for post-exposure prophylaxis," sa
4/24/14 - European Urology Publishes Positive Clinical Trial Results of Topical Botulinum Toxin [Professional Services Close - Up]
The clinical trial was conducted at Tzu Chi University, Hualien, Taiwan. "The possibility of urinary retention and urinary tract infection are the primary drawbacks of the currently available botulinum toxins when treating OAB," according to Michael Chancellor MD, Chief Medical Officer of Lipella Pharmaceuticals. In an accompanying editorial, Prof
4/24/14 - FDA Approves Cochlear Limited Aqua+ Accessory [Travel & Leisure Close - Up]
Cochlear Limited, a provider of implantable hearing solutions, announced that the US Food and Drug Administration has approved the Aqua+ accessory, a waterproof behind-the-ear solution for cochlear implant recipients. The Aqua+ is a form-fitting accessory that allows Cochlear Nucleus 5 and Nucleus 6 Implant recipients2 to swim underwater for up to
4/24/14 - FDA approves Sylvant for rare Castleman's disease
Release date- 23042014- The U.S. Food and Drug Administration today approved Sylvant to treat patients with multicentric Castleman's disease, a rare disorder similar to lymphoma. 'Sylvant is the first FDA- approved drug to treat patients with MCD,' said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Ce
4/24/14 - FINRA Clears Rule 15c2-11 Submission and Issues Symbol PCFTF
VANCOUVER, BC, CANADA/ ACCESSWIRE/ April 24, 2014- Pacific Therapeutics Ltd. is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company is pleased to announce that the Financial Industry Regulatory Authority has approved the Company's rule 15 c2-11.
4/24/14 - GENOCEA Co-Founder Receives TIME Magazine's TIME 100 Honor
Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that TIME magazine has named company co-founder David A. Sinclair, Ph.D., to the 2014 TIME 100, its annual list of the 100 most influential people in the world. Sinclair is a co-joint Professor at the Univers
4/24/14 - Germany : FDA Grants Orphan Drug Designation for Bayer s Investigational Ciprofloxacin Dry Powder for Inhalation for Treatment of NCFB [TendersInfo (India)]
Bayer HealthCare today announced that the U.S. Food and Drug Administration s Office of Orphan Products Development has granted an orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation for the treatment of non-cystic fibrosis bronchiectasis. Jrg Mller, Member of the Bayer HealthCare Executive Committee and Head
4/24/14 - Heartland Institute Experts React to FDA Regulation of E-Cigarettes
The Food and Drug Administration Thursday proposed establishing the first federal regulations on electronic cigarettes, banning sales to minors and requiring FDA approval of the products. "First, for America's 44 million smokers, most of whom want to quit yet cannot with the currently available FDA- approved products, the continued availability of
4/24/14 - HPV: Do Vaccinated Women Still Need a Pap Smear? polyDNA Answers Survey Question and Recommends Novirin Against the Latent HPV
polyDNA's latest survey discovered that 72% of female respondents who had been vaccinated against the human papillomavirus, wanted to know if they still need to have a regular pap smear. "Already got immunized with the HPV vaccine? The formula of this natural antiviral product was shown to reduce HPV symptoms in a post-marketing clinical study tha
4/24/14 - iBio Receives Patent Allowance in China for Fusion Protein Compositions and Technology
iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines. Like Brazil, China is a fast growing healthcare market which has no substantial history or prior commitment to older...
4/24/14 - IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product
Saint Laurent, Quebec- IntelGenx Corp., a Canadian drug delivery company focusing on oral drug delivery, together with RedHill Biopharma Ltd., an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today reported that the U.S. Food and Drug Administration...
4/24/14 - Kamada Announces Significantly Improved Infusion Rate for Glassia
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces a significantly improved infusion rate for Glassia ; this improvement was recently approved by the U.S. Food and Drug Administration. This major improvement was achieved following a post-marketing study conducted by Baxter, and it supports the...
4/24/14 - Kamada Announces Significantly Improved Infusion Rate for Glassia
NESS ZIONA, Israel Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces a significantly improved infusion rate for Glassia ; this improvement was recently approved by the U.S. Food and Drug Administration. This major improvement was achieved following a post-marketing study conducted by Baxter, a
4/24/14 - Karyopharm Initiates Phase 2 Study of Selinexor in Patients With Advanced Gynecologic Malignancies
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export...
4/24/14 - Marken Ready for Orphan Drug Distribution
Marken announced today the release of a new white paper which identifies supply chain solutions for the rapidly growing orphan drug market. In order to respond to this growing trend, Marken has developed a specialized distribution service which can ensure delivery of clinical trial drugs directly to a patient's home or a remote clinic with quality.
Articles(s): 1 - 25 of 243     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415